Competition Piles Up: 100 Teneligliptin Brands Now In India
A hundred teneligliptin brands (including the combination) are said to now jostle for space in the competitive Indian DPP-4 (dipeptidyl peptidase-4) inhibitor market. An uptick in volumes and a significant decline in the prices of teneligliptin probably mean that Merck’s Januvia and Novartis’ Galvus will need to keep a sharp eye on the molecule in the diabetes segment in India.
You may also be interested in...
Novo Nordisk’s new India managing director takes charge amid heightened competition in the diabetes space. The Danish firm stays committed to bringing new products to this market at a faster clip and all eyes will be on the launch trajectory of therapies like semaglutide.
Vildagliptin formulation prices fall by over 70% following the expiry of a patent held by Novartis in India. The innovator, meanwhile, is cashing in on co-marketing agreements with Indian partners like USV and Cipla
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.